Fertility Treatments and MS: Most Relapse Risk Low Today

Credibility

Interest

Key Takeaway

In people with MS, fertility treatments (including IVF) did not raise short-term relapse risk, especially when MS medicines were kept on board.

What They Found

Researchers looked at 124 fertility treatment cycles in 65 people with MS or a first MS-like event. They compared relapses in the year before treatment to the three months after treatment and found no overall increase in relapses. When patients stayed on effective MS medicines during ovarian stimulation, there were no relapses in the three months after treatment. Different fertility methods (like IVF with egg stimulation, embryo transfer alone, or taking pills to stimulate ovulation) had similar low relapse rates. Among those who became pregnant after stimulation, relapses actually dropped in the first trimester, which is similar to pregnancy’s usual calming effect on MS.

Who Should Care and Why

People with MS who are thinking about fertility treatments can take some comfort that, in this study, short-term relapse risk did not go up. Caregivers and partners can use this information to support treatment plans and help patients discuss options with their doctors. Neurologists and fertility doctors should note that continuing disease-modifying therapy (MS medicines) through some fertility steps seemed linked to fewer relapses, so coordinated care matters. For daily life, this means planning fertility workups with your MS team may help reduce interruptions in treatment and lower worry. The biggest benefit is for those on stable MS medicines who want pregnancy — they may safely pursue fertility care with close medical coordination.

Important Considerations

This was a retrospective study, meaning researchers looked back at medical records rather than running a controlled experiment, so some factors may not be fully captured. The group was fairly small and treated at large academic centers, so results might differ in other settings or with different patient groups. The study only measured relapses within three months after treatment, so we don’t know longer-term risks from this data.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Clinical Trials MS Progression

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Neurology(R) neuroimmunology & neuroinflammation often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News